PAI Pharma acquires Nexus, adding an established portfolio of over 20 hospital injectables

PAI Pharma announced on Nov. 12, 2026, that it had acquired Nexus Pharmaceuticals, LLC, adding a company focused on injectable medicines used in hospital settings.¹ Nexus brings a marketed collection of over 20 hospital injectable products, giving the transaction a stated portfolio scale rather than a disclosed purchase price.¹ The announcement does not provide a financial value for the deal, so the number of products is the clearest reported measure of what Nexus contributes.¹ The companies' stated areas overlap in sterile injectables and hospital-focused medicines, while PAI also has an oral liquid medicine business.¹ The acquisition therefore brings Nexus's hospital injectable portfolio into a business already operating across oral liquid and sterile pharmaceutical products.¹ This combination broadens the types of medicines PAI can offer, with Nexus contributing a defined hospital injectable portfolio and PAI already operating in oral liquids and sterile products.¹

Nexus is a U.S.-based specialty pharmaceutical company whose focus is complex injectable medicines, including products for critical care, oncology, and other hospital uses.¹ Those settings describe the kinds of care in which its products are used, not a count of patients, hospitals, or treatments.¹ The reported portfolio figure refers to products in Nexus's established commercial offering, rather than the number of medicines under development or the size of its customer base.¹ Nexus also has products in therapeutic areas that have experienced supply shortages in the past, although the announcement gives no shortage count or duration.¹ The figure of over 20 thus signals the breadth of the commercial portfolio, while the shortage reference describes a feature of some therapies rather than every product.¹ For hospitals using these therapies, the portfolio's breadth and the history of shortages provide relevant context, but the announcement does not establish how supplies will change after the deal.¹

Before the transaction, PAI's business included Ready-to-Dose oral liquid medicines as well as a sterile injectable operation that it described as growing.¹ PAI had recently expanded that injectable business by acquiring Nivagen, which contributed aseptic manufacturing capabilities in Sacramento.¹ The Nivagen reference establishes an earlier addition to PAI's sterile manufacturing activity, while Nexus is a separate acquisition announced afterward in the account.¹ PAI characterized the Nexus deal as building on its investment in domestic sterile manufacturing, connecting the purchase to manufacturing as well as product range.¹ The announcement does not specify that Nexus itself owns manufacturing facilities; it describes the company as working with contract manufacturing partners.¹ PAI's earlier acquisition of Nivagen added aseptic capabilities in Sacramento, while Nexus is described as working with contract manufacturing partners.¹

Nexus brings more than products: PAI said the company has deep customer connections and substantial experience bringing critical therapies through development and commercialization.¹ Nexus's own capabilities include pharmaceutical development and analytical expertise, combined with contract manufacturing partners.¹ It also has established relationships across the U.S. hospital market, a description of its commercial reach rather than a quantified customer total.¹ These capabilities and connections are presented alongside the product portfolio, but no specific number of customers, partner facilities, or development programs is provided.¹ PAI said the acquisition would improve its ability to provide hospitals and healthcare providers with a wider selection of pharmaceutical products.¹ The stated relationships and expertise help explain why PAI sees the deal as relevant to serving hospitals, but they do not quantify how much service capacity will increase.¹

PAI framed the acquisition as part of a strategy to assemble a wider range of essential medicines and increase its presence in hospital and sterile injectable markets.¹ That stated strategy connects Nexus's hospital products with PAI's existing oral liquid medicines and expanding injectable business.¹ PAI also linked the purchase to its domestic sterile manufacturing investment, following the manufacturing capabilities it had gained through Nivagen.¹ The announcement presents the broader range and stronger service capacity as company aims; it does not report measured changes in availability or patient outcomes.¹ Similarly, the past shortages associated with some Nexus therapies are contextual information, not a claim that this acquisition has resolved supply problems.¹ Hospitals are the intended beneficiaries of PAI's wider product offering, but the announcement states a strategic goal rather than documented effects on supply or outcomes.¹

PAI describes itself as a U.S. company that develops, manufactures, and markets oral liquid medicines and ready-to-use sterile injectable and hospital-oriented products.¹ Its stated product work covers oral liquid, sterile, and ready-to-use pharmaceutical products, a description that spans dosage forms and settings.¹ The company's existing oral liquid line and growing injectable activity provide the context for its stated effort to broaden its essential-medicine portfolio.¹ Nexus adds a specialty focus on complex injectables, with critical care, oncology, and other hospital settings identified among the areas it serves.¹ Together, these descriptions explain why PAI presented the acquisition as an expansion of its hospital and sterile injectable activity, without specifying a projected market share.¹ The contrast is between PAI's range of dosage forms and Nexus's concentration on complex injectables, giving the combined business complementary areas of focus.¹

PAI Pharma is a portfolio company of Olympus Partners and is headquartered in Parsippany, New Jersey.¹ PAI says its approach combines product development, manufacturing, and marketing across oral liquid, sterile, and ready-to-use medicines.¹ The company also says it aims to improve patient outcomes through new dosage forms, dependable domestic production, and attention to customers.¹ Those statements set out PAI's description of its priorities; the acquisition announcement does not give outcome data demonstrating a change in patient health.¹ Its stated focus on domestic manufacturing aligns with the announcement's account of investment in sterile production and Nivagen's Sacramento capabilities.¹ For patients and providers, PAI identifies reliable manufacturing and improved outcomes as priorities, but it supplies no outcome measurements tied to the Nexus acquisition.¹

PAI said Nexus's development and commercialization experience, together with its customer relationships, strengthens the combined company's ability to serve hospitals and healthcare providers.¹ The relevant customer group named by PAI is institutional healthcare, while Nexus's relationships are described as extending across the U.S. hospital market.¹ The announcement does not quantify how many providers or hospitals are served, so its account of reach remains qualitative.¹ Nexus's portfolio is measured by its commercial products, whereas its market relationships and expertise are described without comparable numerical measures.¹ This distinction matters when interpreting the deal's scale: the product total is reported, but customer reach, production volume, and the transaction's financial terms are not.¹ Hospitals and healthcare providers are the customers PAI says it can serve more effectively, while the available account describes that intended benefit without measuring its eventual reach.¹

William Blair served as PAI Pharma's exclusive adviser, and Kirkland & Ellis LLP provided legal counsel to PAI.¹ Proskauer Rose LLP acted as legal counsel for Nexus Pharmaceuticals.¹ The announcement identifies these advisers and law firms but does not describe their role in setting terms or provide further transaction details.¹ The public account centers on the acquisition, Nexus's commercial portfolio and capabilities, and PAI's stated plans for hospital and sterile injectable markets.¹ Its wider context is PAI's existing mix of oral liquid medicines and sterile products, its earlier Nivagen expansion, and its stated emphasis on domestic manufacturing.¹ As a result, the announcement offers details about products, capabilities, and strategic aims, while leaving purchase price and several measures of scale unspecified.¹